BLPharma Product 1

EPIVYN is a novel drug that has been developed in the Oncology Research Laboratories of Black Lion Pharmaceuticals, it is a first generation class drug of the type called Low Toxicity Anti-Cancer Drugs (LTACD). EPIVYN has illustrated equivalent or superior cancer killing activities when compared to other global leading anti-cancer agents including Cisplatin, Methotrexate (MTX) and Doxorubicin. The annual sales of cisplatin alone in its different surpass one billion dollars in sales globally. Doxorubicin and Methotrexate have annual sales in the several hundred millions in the worldwide market.

This exciting breakthrough will most likely shed hope for millions of patients that are suffering from different forms of malignant tumors particularly but not limited to those that have been diagnosed with tumors of the type known as squamous cell carcinoma (SCC) cancers which include breast, oral, prostate, kidney, colon and others.

Black Lion Pharmaceuticals is the sole owner of the biotechnological patent and intellectual property of the novel revolutionary anti-cancer drug EPIVYN.